04 · Five things to know · 03
Actinogen’s pivotal Xanamem trial in Alzheimer’s disease missed its primary endpoint
Must read
Actinogen’s pivotal trial of Xanamem in Alzheimer’s disease missed its primary endpoint. The benefit on CDR-SB at week 36 was 0.10 points versus placebo, p = 0.65. The company points to a prespecified subgroup of older patients, but a subgroup after a missed primary is a reason for a new trial, not proof.
From the edition's At a glance, as printed.
Bookmarks need a Mind Club sign-in. How sign-in works
Read it in Five things to know